A Phase 3 interventional study of Evolocumab and Standard of Care in Hyperlipidemia and Mixed Dyslipidemia, sponsored by Amgen. Completed at 363 sites in 25 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2019-06-11.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing evolocumab in Hyperlipidemias — none open to participants now, none under way, none of them phase 3. evolocumab · Hyperlipidemias.
Among the 21 studies testing evolocumab in Hyperlipidemias, this one has the largest enrollment, is one of 7 that started in 2013, is one of 12 in phase 3, and was the 9th registered.
862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.
Browse Hyperlipidemias studies →None of the 21 studies testing evolocumab in Hyperlipidemias is open now. The open studies under Hyperlipidemias, anywhere →
evolocumab: first FDA approval 2015 (REPATHA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 7 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3,681 is above the median of 88 across 735 interventional studies indexed under Hyperlipidemias.
Median enrollment 307 across the 21 interventional studies. Of the 20 that completed or were terminated, 19 (95%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 21 have an industry lead sponsor. The 6 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
17 studies in Hyperlipidemias by Amgen: none open now, none under way, none of them phase 3. Of 17 finished, 17 (100%) have results posted.
Among the 17 studies in Hyperlipidemias by Amgen, this one has the largest enrollment, is one of 7 that started in 2013, is one of 11 in phase 3, and was the 9th registered.
Amgen’s Hyperlipidemias studies by the year they started, since 2010.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing evolocumab in Hyperlipidemias, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 17 in Hyperlipidemias:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will contribute to the evaluation of long-term safety, tolerability and efficacy of evolocumab (AMG 145) in adults with hyperlipidemia and adults with mixed dyslipidemia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received standard of care (SOC) treatment for the first year of the study (SOC-controlled period). At week 48, participants began treatment with evolocumab at a dose of either 140 mg every 2 weeks (Q2W) or 420 mg every month (QM), based on participant choice, for approximately 2 years during the all-investigational product \[all-IP\] period.
Biological: Evolocumab · Drug: Standard of Care
Participants received subcutaneous evolocumab plus standard of care during the first year of the study (SOC-controlled period) and for approximately 2 years during the all-IP period. Evolocumab was administered at a dose of 140 mg every 2 weeks (Q2W) or 420 mg every month (QM) based on participant choice.
Biological: Evolocumab · Drug: Standard of Care
Administered by subcutaneous injection either every 2 weeks or once a month (patient preference) using a prefilled autoinjector pen
Also known as: AMG 145, Repatha
Standard of care therapy as per local practices. This could include prescribed therapies and/or dietary/exercise regimes
Number of Participants With Adverse Events
Adverse event (AE) severity assessments were made using National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) grading, version 4.0, where grade 1 = mild AE, grade 2 = moderate AE, Grade 3 = severe AE, grade 4 = life-threatening AE and Grade 5 = death due to AE.
Time frame: 48 weeks in the SOC-controlled period and up to 2 years in the All-IP period
Percent Change From Baseline in LDL-C at Weeks 48 and 104
Time frame: Baseline of the parent study and weeks 48 amd 104
Change From Baseline in LDL-C at Weeks 48 and 104
Time frame: Baseline of the parent study and weeks 48 amd 104
Participants were enrolled at 365 study centers in 24 countries in Europe, North America, and Asia Pacific from 23 April 2013 to 31 August 2015.
| Milestone | Standard of Care | Evolocumab + Standard of Care |
|---|---|---|
| Started | 1227 | 2454 |
| Received evolocumab | 5 | 2452 |
| Completed | 1197 | 2391 |
| Not completed | 30 | 63 |
| Withdrew: Withdrawal by subject | 20 | 49 |
| Withdrew: Decision by sponsor | 2 | 1 |
| Withdrew: Lost to follow-up | 3 | 8 |
| Withdrew: Death | 5 | 5 |
| Milestone | Standard of Care | Evolocumab + Standard of Care |
|---|---|---|
| Started | 1197 | 2391 |
| Received evolocumab | 1152 | 2291 |
| Completed | 1079 | 2196 |
| Not completed | 118 | 195 |
| Withdrew: Withdrawal by subject | 78 | 117 |
| Withdrew: Decision by sponsor | 8 | 11 |
| Withdrew: Lost to follow-up | 27 | 51 |
| Withdrew: Death | 5 | 16 |
Adverse event (AE) severity assessments were made using National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) grading, version 4.0, where grade 1 = mild AE, grade 2 = moderate AE, Grade 3 = severe AE, grade 4 = life-threatening AE and Grade 5 = death due to AE.
| Participants | Year 1: Standard of Care | Year 1: Evolocumab + Standard of Care | Years 2-3: SOC / Evolocumab + SOC | Years 2-3: Evolocumab + SOC / Evolocumab + SOC |
|---|---|---|---|---|
| All adverse events | 796 | 1655 | 929 | 1789 |
| Adverse events ≥ grade 2 | 519 | 1070 | 700 | 1339 |
| Adverse events ≥ grade 3 | 124 | 225 | 214 | 379 |
| Adverse events ≥ grade 4 | 7 | 17 | 11 | 35 |
| Serious adverse events | 104 | 195 | 178 | 332 |
| AEs leading to discontinuation of evolocumab | 0 | 55 | 26 | 42 |
| Fatal adverse events | 5 | 5 | 3 | 16 |
| Device related adverse events | 0 | 57 | 25 | 45 |
| percent change | Standard of Care | Evolocumab + Standard of Care |
|---|---|---|
| Week 48 | 7.43 ± 38.93 | -51.59 ± 28.88 |
| Week 104 | -49.96 ± 33.29 | -50.31 ± 30.34 |
| mg/dL | Standard of Care | Evolocumab + Standard of Care |
|---|---|---|
| Week 48 | 0.4 ± 43.9 | -68.8 ± 46.6 |
| Week 104 | -66.4 ± 50.1 | -67.2 ± 46.6 |
Collected over 48 weeks in the SOC-controlled period and up to 2 years in the All-IP period.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Year 1: Standard of Care | 5/1,227 (0.4%) | 104/1,227 (8.5%) | 334/1,227 (27.2%) |
| Year 1: Evolocumab + Standard of Care | 5/2,454 (0.2%) | 195/2,454 (7.9%) | 681/2,454 (27.8%) |
| Years 2-3: SOC / Evolocumab + SOC | 5/1,197 (0.4%) | 181/1,197 (15.1%) | 498/1,197 (41.6%) |
| Years 2-3: Evolocumab + SOC / Evolocumab + SOC | 16/2,391 (0.7%) | 344/2,391 (14.4%) | 928/2,391 (38.8%) |
| Years 2-3: Total | 21/3,588 (0.6%) | 525/3,588 (14.6%) | 1,426/3,588 (39.7%) |
| Event | Year 1: Standard of Care | Year 1: Evolocumab + Standard of Care | Years 2-3: SOC / Evolocumab + SOC | Years 2-3: Evolocumab + SOC / Evolocumab + SOC | Years 2-3: Total |
|---|---|---|---|---|---|
| OsteoarthritisMusculoskeletal and connective tissue disorders | 5/1227 | 12/2454 | 22/1197 | 22/2391 | 44/3588 |
| Angina pectorisCardiac disorders | 0/1227 | 7/2454 | 10/1197 | 8/2391 | 18/3588 |
| Non-cardiac chest painGeneral disorders | 3/1227 | 4/2454 | 10/1197 | 8/2391 | 18/3588 |
| Atrial fibrillationCardiac disorders | 3/1227 | 1/2454 | 7/1197 | 7/2391 | 14/3588 |
| Acute myocardial infarctionCardiac disorders | 4/1227 | 8/2454 | 3/1197 | 12/2391 | 15/3588 |
| PneumoniaInfections and infestations | 1/1227 | 0/2454 | 4/1197 | 12/2391 | 16/3588 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 1/1227 | 1/2454 | 6/1197 | 6/2391 | 12/3588 |
| Angina unstableCardiac disorders | 6/1227 | 7/2454 | 4/1197 | 11/2391 | 15/3588 |
| CholelithiasisHepatobiliary disorders | 0/1227 | 3/2454 | 5/1197 | 0/2391 | 5/3588 |
| Aortic stenosisVascular disorders | 0/1227 | 1/2454 | 4/1197 | 0/2391 | 4/3588 |
| Event | Year 1: Standard of Care | Year 1: Evolocumab + Standard of Care | Years 2-3: SOC / Evolocumab + SOC | Years 2-3: Evolocumab + SOC / Evolocumab + SOC | Years 2-3: Total |
|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 108/1227 | 201/2454 | 151/1197 | 253/2391 | 404/3588 |
| Upper respiratory tract infectionInfections and infestations | 55/1227 | 104/2454 | 99/1197 | 178/2391 | 277/3588 |
| HypertensionVascular disorders | 56/1227 | 87/2454 | 78/1197 | 180/2391 | 258/3588 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 38/1227 | 106/2454 | 80/1197 | 162/2391 | 242/3588 |
| Back painMusculoskeletal and connective tissue disorders | 35/1227 | 83/2454 | 78/1197 | 147/2391 | 225/3588 |
| BronchitisInfections and infestations | 43/1227 | 78/2454 | 70/1197 | 132/2391 | 202/3588 |
| MyalgiaMusculoskeletal and connective tissue disorders | 43/1227 | 88/2454 | 61/1197 | 67/2391 | 128/3588 |
| InfluenzaInfections and infestations | 28/1227 | 66/2454 | 60/1197 | 115/2391 | 175/3588 |
All randomized participants
| Age, Continuous(years) | Standard of Care | Evolocumab + Standard of Care | Total |
|---|---|---|---|
| Mean | 58.8 ± 10.7 | 58.6 ± 10.7 | 58.7 ± 10.7 |
| Age, Customized(Participants) | Standard of Care | Evolocumab + Standard of Care | Total |
|---|---|---|---|
| < 65 years | 823 | 1665 | 2488 |
| ≥ 65 years | 404 | 789 | 1193 |
| Sex: Female, Male(Participants) | Standard of Care | Evolocumab + Standard of Care | Total |
|---|---|---|---|
| Female | 560 | 1176 | 1736 |
| Male | 667 | 1278 | 1945 |
| Ethnicity (NIH/OMB)(Participants) | Standard of Care | Evolocumab + Standard of Care | Total |
|---|---|---|---|
| Hispanic or Latino | 58 | 109 | 167 |
| Not Hispanic or Latino | 1169 | 2345 | 3514 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Standard of Care | Evolocumab + Standard of Care | Total |
|---|---|---|---|
| American Indian or Alaska Native | 2 | 5 | 7 |
| Asian | 152 | 288 | 440 |
| Black or African American | 49 | 84 | 133 |
| Native Hawaiian or Other Pacific Islander | 2 | 2 | 4 |
| White | 1003 | 2041 | 3044 |
| Other | 16 | 30 | 46 |
| Mixed Race | 3 | 4 | 7 |
| Region(Participants) | Standard of Care | Evolocumab + Standard of Care | Total |
|---|---|---|---|
| North America | 514 | 1001 | 1515 |
| Europe | 504 | 1018 | 1522 |
| Asia Pacific | 209 | 435 | 644 |
| Parent Study Baseline Low-density Lipoprotein Cholesterol (LDL-C) Concentration(mg/dL) | Standard of Care | Evolocumab + Standard of Care | Total |
|---|---|---|---|
| Mean | 125.8 ± 49.3 | 127.4 ± 51.7 | 126.9 ± 50.9 |
Showing the first 100 of 363 sites across 25 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2013 to primary completion in May 2018, 61 months.
Results were first posted in Jun 2019, 1 year after primary completion.
Of 51 industry-sponsored phase 3 interventional studies under Hyperlipidemias, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 61 months is above that.
Counting every sponsor, half of 57 studies reached it within 18 months; a quarter within 11 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Evolocumab